The incidence of epilepsy rises rapidly after age 60, and many elderly are being treated with phenytoin (PHT), carbamazepine (CBZ) and valproic acid (VPA). These older antiepileptic drugs (AEDs) have many shortcomings including complex metabolism by the cytochrome P450 and glucuronidation enzyme systems and have been shown to be inducers and inhibitors in these systems. This makes them prone to many drug interactions involving both clearance and protein binding. This is a multifaceted issue; AED efficacy and toxicity may be altered by co-medications, and AEDs can affect the efficacy and toxicity of co-medications. Because an elderly patient uses an average of 6 medications, the risk of medication interactions in this age group with these older AEDs is very high. Three newer AEDs, lamotrigine (LTG), topiramate (TPM) and levetiracetam (LEV) appear to have more favorable drug-drug interaction profiles; all have low protein binding and fewer or no metabolic interactions. However, these newer drugs have not been studied sufficiently in the eldedy and more detailed information regarding the pharmacokinetio and pharmacodynamic properties of these is needed. The difficulty in obtaining blood samples from this population makes inclusion in standard pharrnacokinetic studies difficult. This project will use nonlinear mixed effects model (NONMEM) that employs both pharmacokinetics and statistics will be used to determine pharrnacokinetic parameters of these three new drugs. This powerful method allows the use of routinely collected data to be used and avoids the risks and expense encountered in intensive pharmacokinetic studies. With this method, not only can the drug clearance be determined for a population, but it can also be determined for an individual. Factors (age, race, gender, smoking, etc.) that affect drug clearance can also be determined. In addition, the relationship between serum drug concentration and seizure type will be determined for LTG, TPM, and LEV. We will have access to approximately 450 persons >65 years of age receiving LTG, 420 receiving TPM and 337 receiving LEV from several active epilepsy practices in 3 cities (Minneapolis, Miami, Atlanta) and data from more than 1500 younger adults on each of these AEDs. In addition we will use our tools to analyze data from the ongoing perspective VA cooperative study of LTG projected to enroll 240 subjects receiving LTG as initial treatment. The VA data will determine the relationship between drug concentrations and adverse events and seizure frequency for LTG providing both pharmacokinetic and pharmacodynamic information in the elderly. This project along with Projects 1 and 2 will provide pharmacokinetic data and identify and quantitate the factors that influence the pharmacokinetics of LTG, LEV, and TPM. This information can be used to guide dosing requirements needed to obtain target serum concentrations in the elderly to achieve seizure control and avoid drug toxicity.

Agency
National Institute of Health (NIH)
Institute
National Institute of Neurological Disorders and Stroke (NINDS)
Type
Specialized Center (P50)
Project #
5P50NS016308-26
Application #
7281604
Study Section
Project Start
Project End
Budget Start
2006-09-01
Budget End
2007-08-31
Support Year
26
Fiscal Year
2006
Total Cost
$334,522
Indirect Cost
Name
University of Minnesota Twin Cities
Department
Type
DUNS #
555917996
City
Minneapolis
State
MN
Country
United States
Zip Code
55455
Conway, Jeannine M; Eberly, Lynn E; Collins, Joseph F et al. (2017) Factors in Variability of Serial Gabapentin Concentrations in Elderly Patients with Epilepsy. Pharmacotherapy 37:1197-1203
Polepally, Akshanth R; Remmel, Rory P; Brundage, Richard C et al. (2015) Steady-state pharmacokinetics and bioavailability of immediate-release and extended-release formulations of lamotrigine in elderly epilepsy patients: Use of stable isotope methodology. J Clin Pharmacol 55:1101-8
Patel, Sima I; Birnbaum, Angela K; Cloyd, James C et al. (2015) Intravenous and Intramuscular Formulations of Antiseizure Drugs in the Treatment of Epilepsy. CNS Drugs 29:1009-22
Conway, Jeannine M; Birnbaum, Angela K; Leppik, Ilo E et al. (2014) Safety of an intravenous formulation of lamotrigine. Seizure 23:390-2
Ghodke-Puranik, Yogita; Thorn, Caroline F; Lamba, Jatinder K et al. (2013) Valproic acid pathway: pharmacokinetics and pharmacodynamics. Pharmacogenet Genomics 23:236-41
Ahmed, Ghada F; Brundage, Richard C; Marino, Susan E et al. (2013) Population pharmacokinetics of unbound and total drug concentrations following intravenously administered carbamazepine in elderly and younger adult patients with epilepsy. J Clin Pharmacol 53:276-84
Puranik, Yogita Ghodke; Birnbaum, Angela K; Marino, Susan E et al. (2013) Association of carbamazepine major metabolism and transport pathway gene polymorphisms and pharmacokinetics in patients with epilepsy. Pharmacogenomics 14:35-45
Conway, Jeannine M; Birnbaum, Angela K; Marino, Susan E et al. (2012) A sensitive capillary GC-MS method for analysis of topiramate from plasma obtained from single-dose studies. Biomed Chromatogr 26:1071-6
Punyawudho, Baralee; Ramsay, Eugene R; Brundage, Richard C et al. (2012) Population pharmacokinetics of carbamazepine in elderly patients. Ther Drug Monit 34:176-81
Marino, S E; Birnbaum, A K; Leppik, I E et al. (2012) Steady-state carbamazepine pharmacokinetics following oral and stable-labeled intravenous administration in epilepsy patients: effects of race and sex. Clin Pharmacol Ther 91:483-8

Showing the most recent 10 out of 96 publications